Solriamfetol beneficial for adults with attention-deficit/hyperactivity disorder, shows clinical trial
USA: A recent clinical trial published in the Journal of Clinical Psychiatry has supported solriamfetol as a novel and effective treatment for the management of attention deficit/hyperactivity disorder (ADHD) in adults.
Solriamfetol is currently approved in the United States for treating excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. The drug increases the amounts of certain natural substances in the brain- specifically, dopamine and norepinephrine controls sleep and wakefulness, thus sharing some of the properties of current ADHD medications.
Although several medications are approved to treat attention-deficit/hyperactivity disorder (ADHD), some individuals experience limited benefits from the drugs or develop side effects from their use.
To test the potential of solriamfetol for treating ADHD, researchers randomized 60 adults with the condition to solriamfetol (75 or 150 mg) or placebo for 6 weeks. Participants were interviewed serially using the primary outcome measure for the trial, the Adult ADHD Investigator Symptom Rating Scale (AISRS). ADHD symptoms were further evaluated by a patient-reported measure. ADHD-related impairment was assessed using the Clinical Global Impressions scale (CGI), and executive function challenges were measured using the participant-rated Behavior Rating Inventory of Executive Function-Adult Form (BRIEF-A).
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.